{"generic":"Escitalopram Oxalate","drugs":["Escitalopram Oxalate","Lexapro"],"mono":[{"id":"926990-s-0","title":"Generic Names","mono":"Escitalopram Oxalate"},{"id":"926990-s-1","title":"Dosing and Indications","sub":[{"id":"926990-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Cerebrovascular accident - Depression; Prophylaxis:<\/b> 65 years and younger, 10 mg\/day ORALLY (study dosing)<\/li><li><b>Cerebrovascular accident - Depression; Prophylaxis:<\/b> older than 65 years, 5 mg\/day ORALLY (study dosing)<\/li><li><b>Generalized anxiety disorder:<\/b> initial, 10 mg\/day ORALLY as a single dose in the morning or evening<\/li><li><b>Generalized anxiety disorder:<\/b> maintenance, 10 mg\/day ORALLY, may increase to 20 mg\/day ORALLY only after a minimum of 1 week<\/li><li><b>Major depressive disorder:<\/b> initial, 10 mg\/day ORALLY as a single dose in the morning or evening<\/li><li><b>Major depressive disorder:<\/b> maintenance, 10 mg\/day ORALLY, may increase to 20 mg\/day ORALLY only after a minimum of 1 week<\/li><li><b>Mixed anxiety and depressive disorder:<\/b> 10 to 20 mg ORALLY daily (study dosing)<\/li><li><b>Obsessive-compulsive disorder:<\/b> 10 to 20 mg\/day ORALLY (study dosing)<\/li><li><b>Panic disorder:<\/b> mean dose, 10.8 mg\/day ORALLY (study dosing)<\/li><li><b>Premenstrual dysphoric disorder:<\/b> 5 mg ORALLY on day 1, 10 mg ORALLY on day 2, and 20 mg ORALLY daily thereafter, beginning on day of ovulation until the first day of menstruation (study dosing)<\/li><\/ul>"},{"id":"926990-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Major depressive disorder:<\/b> age 12 years and older: initial, 10 mg\/day ORALLY as a single dose in the morning or evening<\/li><li><b>Major depressive disorder:<\/b> age 12 years and older: maintenance, 10 mg\/day ORALLY, may increase to 20 mg\/day ORALLY only after a minimum of 3 weeks<\/li><\/ul>"},{"id":"926990-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>tapering or discontinuation of therapy:<\/b> if intolerable symptoms occur, the previously prescribed dose may be reinstated and then the dose may be reduced at a more gradual rate<\/li><li><b>geriatric:<\/b> 10 mg\/day ORALLY<\/li><li><b>hepatic impairment:<\/b> 10 mg\/day ORALLY<\/li><li><b>renal impairment, mild to moderate:<\/b> no dose adjustments recommended<\/li><li><b>renal impairment, severe:<\/b> use caution<\/li><\/ul>"},{"id":"926990-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Generalized anxiety disorder<\/li><li>Major depressive disorder<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Cerebrovascular accident - Depression; Prophylaxis<\/li><li>Mixed anxiety and depressive disorder<\/li><li>Obsessive-compulsive disorder<\/li><li>Panic disorder<\/li><li>Premenstrual dysphoric disorder<\/li><\/ul>"}]},{"id":"926990-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet; Solution)<\/b><br\/>Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder (MDD) and other psychiatric disorders in short-term studies. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared with placebo in adults beyond age 24, and there was a reduction in risk with antidepressants compared with placebo in adults aged 65 or older. This risk must be balanced with the clinical need. Monitor patients closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Not approved for use in pediatric patients less than 12 years of age.<br\/>"},{"id":"926990-s-3","title":"Contraindications\/Warnings","sub":[{"id":"926990-s-3-9","title":"Contraindications","mono":"<ul><li>increased risk of serotonin syndrome with concomitant use with an MAOI, including linezolid or IV methylene blue, or use of escitalopram within 14 days of discontinuing an MAOI used to treat psychiatric disorders, or use of an MAOI used to treat psychiatric disorders within 14 days of discontinuing escitalopram<\/li><li>concomitant use of pimozide<\/li><li>hypersensitivity to citalopram, escitalopram, or any other component of the product<\/li><\/ul>"},{"id":"926990-s-3-10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder (MDD) and other psychiatric disorders, especially during the first few months of therapy or dose adjustments; monitoring recommended; discontinuation may be required<\/li><li>-- avoid use in pediatric patients under 12 years of age<\/li><li>Endocrine and Metabolic:<\/li><li>-- hyponatremia, usually the result of SIADH, has occurred, especially in volume-depleted and elderly patients or with concurrent diuretic therapy; discontinue if symptoms develop<\/li><li>Hematologic:<\/li><li>-- bleeding events, including life-threatening hemorrhages, have been reported with SSRIs and serotonin norepinephrine reuptake inhibitors; increased risk possible with concomitant use of NSAIDs, aspirin, warfarin, and other anticoagulants<\/li><li>Hepatic:<\/li><li>- hepatic impairment; dosage adjustment may be necessary<\/li><li>Neurologic:<\/li><li>-- history of seizure disorder<\/li><li>Ophthalmic Effects:<\/li><li>-- worsening of angle-closure glaucoma may occur in patients with anatomically narrow angle without a patent iridectomy<\/li><li>Psychiatric:<\/li><li>-- antidepressant therapy may trigger a mixed\/manic episode in patients with underlying bipolar disorder; baseline screening recommended<\/li><li>-- hypomania or mania have been reported; use caution in patients with a history of mania<\/li><li>Renal:<\/li><li>-- severe renal impairment<\/li><li>Other:<\/li><li>-- life-threatening serotonin syndrome has been reported, often during concurrent use with other serotonergic drugs (ie, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, St John's wort) or drugs than impair the metabolism of serotonin (ie, MAOIs, linezolid, methylene blue); monitoring recommended and discontinue if suspected<\/li><li>-- serious withdrawal symptoms upon abrupt discontinuation have been reported; monitoring and gradual withdrawal are recommended when possible<\/li><li>-- conditions or diseases that alter metabolism or hemodynamic responses<\/li><li>-- elderly patients; dosage adjustment may be necessary<\/li><li>Concomitant use:<\/li><li>-- alcohol is not recommended<\/li><li>-- serotonin precursors such as tryptophan, other SSRIs, or serotonin norepinephrine reuptake inhibitors is not recommended<\/li><\/ul>"},{"id":"926990-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Escitalopram: C (FDA)<\/li><li>Escitalopram: C (AUS)<\/li><\/ul>"},{"id":"926990-s-3-12","title":"Breast Feeding","mono":"Escitalopram: Micromedex: Infant risk has been demonstrated.<br\/>"}]},{"id":"926990-s-4","title":"Drug Interactions","sub":[{"id":"926990-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Clorgyline (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Furazolidone (theoretical)<\/li><li>Iproniazid (theoretical)<\/li><li>Isocarboxazid (theoretical)<\/li><li>Lazabemide (theoretical)<\/li><li>Linezolid (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Methylene Blue (theoretical)<\/li><li>Metoclopramide (theoretical)<\/li><li>Moclobemide (theoretical)<\/li><li>Pargyline (theoretical)<\/li><li>Phenelzine (theoretical)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Procarbazine (theoretical)<\/li><li>Rasagiline (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Selegiline (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Tranylcypromine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"926990-s-4-14","title":"Major","mono":"<ul><li>Abciximab (probable)<\/li><li>Aceclofenac (probable)<\/li><li>Acemetacin (probable)<\/li><li>Acenocoumarol (probable)<\/li><li>Alfuzosin (theoretical)<\/li><li>Almotriptan (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amoxapine (theoretical)<\/li><li>Amtolmetin Guacil (probable)<\/li><li>Anagrelide (theoretical)<\/li><li>Ancrod (probable)<\/li><li>Anisindione (probable)<\/li><li>Antithrombin III Human (probable)<\/li><li>Apixaban (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Ardeparin (probable)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Aspirin (probable)<\/li><li>Astemizole (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Bivalirudin (probable)<\/li><li>Bromfenac (probable)<\/li><li>Bufexamac (probable)<\/li><li>Bupropion (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Celecoxib (probable)<\/li><li>Certoparin (probable)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Choline Salicylate (probable)<\/li><li>Cilostazol (probable)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clonixin (probable)<\/li><li>Clopidogrel (probable)<\/li><li>Clozapine (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dalteparin (probable)<\/li><li>Danaparoid (probable)<\/li><li>Darunavir (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Defibrotide (probable)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Dermatan Sulfate (probable)<\/li><li>Desipramine (probable)<\/li><li>Desirudin (probable)<\/li><li>Deslorelin (theoretical)<\/li><li>Desvenlafaxine (theoretical)<\/li><li>Dexibuprofen (probable)<\/li><li>Dexketoprofen (probable)<\/li><li>Dextromethorphan (theoretical)<\/li><li>Diclofenac (probable)<\/li><li>Dicumarol (probable)<\/li><li>Diflunisal (probable)<\/li><li>Dipyridamole (probable)<\/li><li>Dipyrone (probable)<\/li><li>Disopyramide (theoretical)<\/li><li>Dofetilide (theoretical)<\/li><li>Dolasetron (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Doxepin (theoretical)<\/li><li>Droperidol (theoretical)<\/li><li>Duloxetine (theoretical)<\/li><li>Ebastine (theoretical)<\/li><li>Eletriptan (theoretical)<\/li><li>Enoxaparin (probable)<\/li><li>Eptifibatide (probable)<\/li><li>Eribulin (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Etodolac (probable)<\/li><li>Etofenamate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Famotidine (theoretical)<\/li><li>Felbamate (theoretical)<\/li><li>Felbinac (probable)<\/li><li>Fenoprofen (probable)<\/li><li>Fentanyl (theoretical)<\/li><li>Fepradinol (probable)<\/li><li>Feprazone (probable)<\/li><li>Fingolimod (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Floctafenine (probable)<\/li><li>Flufenamic Acid (probable)<\/li><li>Fluoxetine (theoretical)<\/li><li>Flurbiprofen (probable)<\/li><li>Fluvoxamine (theoretical)<\/li><li>Fondaparinux (probable)<\/li><li>Formoterol (theoretical)<\/li><li>Foscarnet (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Frovatriptan (probable)<\/li><li>Galantamine (theoretical)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (theoretical)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Heparin (probable)<\/li><li>Histrelin (theoretical)<\/li><li>Hydroquinidine (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Hydroxytryptophan (theoretical)<\/li><li>Ibuprofen (probable)<\/li><li>Ibuprofen Lysine (probable)<\/li><li>Ibutilide (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Indomethacin (probable)<\/li><li>Iobenguane I 123 (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Ketoprofen (probable)<\/li><li>Ketorolac (probable)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Lorcaserin (theoretical)<\/li><li>Lornoxicam (probable)<\/li><li>Loxoprofen (probable)<\/li><li>Lumefantrine (theoretical)<\/li><li>Lumiracoxib (probable)<\/li><li>Meclofenamate (probable)<\/li><li>Mefenamic Acid (probable)<\/li><li>Mefloquine (theoretical)<\/li><li>Meloxicam (probable)<\/li><li>Meperidine (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Miconazole (probable)<\/li><li>Mifepristone (theoretical)<\/li><li>Milnacipran (theoretical)<\/li><li>Mirtazapine (theoretical)<\/li><li>Mizolastine (theoretical)<\/li><li>Morniflumate (probable)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nabumetone (probable)<\/li><li>Nadroparin (probable)<\/li><li>Nafarelin (theoretical)<\/li><li>Naproxen (probable)<\/li><li>Naratriptan (probable)<\/li><li>Nepafenac (probable)<\/li><li>Niflumic Acid (probable)<\/li><li>Nilotinib (theoretical)<\/li><li>Nimesulide (probable)<\/li><li>Norfloxacin (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Olanzapine (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Oxaprozin (probable)<\/li><li>Oxycodone (probable)<\/li><li>Oxyphenbutazone (probable)<\/li><li>Paliperidone (theoretical)<\/li><li>Palonosetron (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Parecoxib (probable)<\/li><li>Parnaparin (probable)<\/li><li>Paroxetine (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Pentamidine (theoretical)<\/li><li>Pentosan Polysulfate Sodium (probable)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Perphenazine (theoretical)<\/li><li>Phenindione (probable)<\/li><li>Phenprocoumon (probable)<\/li><li>Phenylbutazone (probable)<\/li><li>Piketoprofen (probable)<\/li><li>Piroxicam (probable)<\/li><li>Prasugrel (probable)<\/li><li>Probucol (theoretical)<\/li><li>Procainamide (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Proglumetacin (probable)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Propionic Acid (probable)<\/li><li>Propyphenazone (probable)<\/li><li>Proquazone (probable)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Reviparin (probable)<\/li><li>Rilpivirine (theoretical)<\/li><li>Risperidone (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Rizatriptan (probable)<\/li><li>Rofecoxib (probable)<\/li><li>Salicylic Acid (probable)<\/li><li>Salsalate (probable)<\/li><li>Sertindole (theoretical)<\/li><li>Sertraline (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Sibutramine (probable)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Sodium Salicylate (probable)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>St John's Wort (probable)<\/li><li>Sulindac (probable)<\/li><li>Sumatriptan (probable)<\/li><li>Sunitinib (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><li>Tamoxifen (theoretical)<\/li><li>Tapentadol (theoretical)<\/li><li>Telaprevir (probable)<\/li><li>Telavancin (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tenoxicam (probable)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Tiaprofenic Acid (probable)<\/li><li>Ticlopidine (probable)<\/li><li>Tinzaparin (probable)<\/li><li>Tirofiban (probable)<\/li><li>Tizanidine (theoretical)<\/li><li>Tolfenamic Acid (probable)<\/li><li>Tolmetin (probable)<\/li><li>Tolterodine (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Tramadol (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Tryptophan (theoretical)<\/li><li>Valdecoxib (probable)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Venlafaxine (theoretical)<\/li><li>Vilanterol (theoretical)<\/li><li>Vilazodone (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Vorinostat (theoretical)<\/li><li>Vortioxetine (theoretical)<\/li><li>Warfarin (probable)<\/li><li>Zolmitriptan (probable)<\/li><\/ul>"},{"id":"926990-s-4-15","title":"Moderate","mono":"<ul><li>Boceprevir (established)<\/li><li>Cimetidine (probable)<\/li><li>Ginkgo (probable)<\/li><li>Hydrocodone (probable)<\/li><li>Lamotrigine (probable)<\/li><li>Lithium (established)<\/li><\/ul>"}]},{"id":"926990-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Diaphoresis (3% to 8%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (2%), Constipation (3% to 6%), Diarrhea (6% to 14%), Indigestion (2% to 6%), Nausea (15% to 18%), Vomiting (up to 3%), Xerostomia (4% to 9%)<\/li><li><b>Neurologic:<\/b>Dizziness (4% to 7%), Headache (24%), Insomnia (7% to 14%), Somnolence (4% to 13%)<\/li><li><b>Reproductive:<\/b>Disorder of ejaculation (9% to 14%), Erectile dysfunction (3%), Orgasm incapacity (females, 2% to 6%), Reduced libido (3% to 7%)<\/li><li><b>Other:<\/b>Fatigue (5% to 8%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Psychiatric:<\/b>Depression, worsening, Suicidal thoughts, Suicide<\/li><li><b>Other:<\/b>Serotonin syndrome<\/li><\/ul>"},{"id":"926990-s-6","title":"Drug Name Info","sub":{"0":{"id":"926990-s-6-17","title":"US Trade Names","mono":"Lexapro<br\/>"},"2":{"id":"926990-s-6-19","title":"Class","mono":"<ul><li>Antidepressant<\/li><li>Serotonin Reuptake Inhibitor<\/li><\/ul>"},"3":{"id":"926990-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"926990-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"926990-s-7","title":"Mechanism Of Action","mono":"Escitalopram oxalate, a selective serotonin reuptake inhibitor (SSRI) and S-enantiomer of racemic citalopram, enhances serotonergic activity in the central nervous system (CNS) as a result of its inhibition of serotonin (5-HT) reuptake in CNS neurons. It possesses no or very low affinity for serotonergic (5-HT1-7), alpha- and beta-adrenergic, dopamine (D1-5), histamine (H1-3), muscarinic (M1-5), and benzodiazepine receptors as well as various ion channels including Na+, K+, Cl-, and Ca++ channels.<br\/>"},{"id":"926990-s-8","title":"Pharmacokinetics","sub":[{"id":"926990-s-8-23","title":"Absorption","mono":"<ul><li>Citalopram, Bioavailability: (IV), about 80%<\/li><li>Escitalopram oxalate, Oral: time to peak concentration, about 5 h<\/li><li>Escitalopram oxalate, Effect of food: no effect<\/li><\/ul>"},{"id":"926990-s-8-24","title":"Distribution","mono":"<ul><li>Citalopram, Vd: about 12 L\/kg<\/li><li>Escitalopram oxalate, Protein binding: approximately 56%<\/li><\/ul>"},{"id":"926990-s-8-25","title":"Metabolism","mono":"<ul><li>Escitalopram oxalate-Hepatic; P450 CYP3A4 and CYP2C19; N-demethylation<\/li><li>Metabolites: S-demethylcitalopram (S-DCT) and S-didemethylcitalopram (SDDCT)<\/li><\/ul>"},{"id":"926990-s-8-26","title":"Excretion","mono":"Renal: 10% as S-DCT, 8% unchanged <br\/>"},{"id":"926990-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Escitalopram oxalate: 27 h to 32 h (mean)<\/li><li>Escitalopram oxalate, elderly: increased by approximately 50%<\/li><li>Citalopram, reduced hepatic function: doubled<\/li><\/ul>"}]},{"id":"926990-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>allow at least 14 days between the discontinuation of an MAOI and initiation of escitalopram or the discontinuation of escitalopram and initiation of treatment with an MAOI<\/li><li>may take without regard to meals<\/li><\/ul>"},{"id":"926990-s-10","title":"Monitoring","mono":"<ul><li>reduction or resolution of signs\/symptoms indicates efficacy<\/li><li>maintenance therapy; periodically reevaluate to determine clinical need<\/li><li>worsening of depression, suicidality, or unusual changes in behavior; especially during first few months of therapy or with dose adjustments<\/li><li>bipolar disorder; prior to initiating therapy in patients with depressive symptoms<\/li><li>discontinuation symptoms; particularly with abrupt treatment cessation<\/li><li>serotonin syndrome; especially if coadministered with other serotonergic drugs<\/li><li>sexual dysfunction<\/li><li>growth and weight; pediatric patients<\/li><\/ul>"},{"id":"926990-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Oral Solution: 5 MG\/5 ML<\/li><li>Oral Tablet: 5 MG, 10 MG, 20 MG<\/li><\/ul><\/li><li><b>Lexapro<\/b><br\/><ul><li>Oral Solution: 5 MG\/5 ML<\/li><li>Oral Tablet: 5 MG, 10 MG, 20 MG<\/li><\/ul><\/li><\/ul>"},{"id":"926990-s-12","title":"Toxicology","sub":[{"id":"926990-s-12-31","title":"Clinical Effects","mono":"<b>CITALOPRAM AND RELATED AGENTS <\/b><br\/>USES: Selective serotonin reuptake inhibitors (SSRIs) used to treat major depressive disorder. Also used for treating obsessive-compulsive disorder, panic disorder, premenstrual dysphoric syndrome, anxiety disorder, and posttraumatic stress disorder. PHARMACOLOGY: Selectively inhibits the presynaptic reuptake of serotonin. Stimulation of postsynaptic 5-HT1 receptors results in the antidepressant and anxiolytic effects. TOXICOLOGY: Many of the toxic effects are mediated by stimulation of the 5-HT2 receptors causing excessive serotonin effect or serotonin syndrome. EPIDEMIOLOGY: Overdose is becoming increasingly frequent. Overdose of a single SSRI is usually well tolerated with mild to moderate severity. More severe toxicity (serotonin syndrome) may develop when another agent that increases CNS serotonin is ingested in addition to citalopram. MILD TO MODERATE TOXICITY: Agitation, confusion, tremor, nausea, vomiting, hyperreflexia, occasional clonus and myoclonus, hypoglycemia, hypertension, and bradycardia. SEVERE TOXICITY: Seizure, rigidity, hyperthermia, hypertension or hypotension, QRS and QTc interval prolongation, coma, and rarely, death. Serotonin syndrome may develop and is characterized by mental status changes (confusion, hypomania), agitation, myoclonus, hyperreflexia, diaphoresis, shivering, tremor, diarrhea, incoordination, and fever. Wide complex tachyarrhythmias, torsade de pointes, and cardiac arrest have all been observed after massive citalopram overdose, sometimes occurring quite late after the ingestion. Neuroleptic malignant syndrome has been reported following a citalopram overdose. ADVERSE EFFECTS: COMMON: Nausea, vomiting, dry mouth, somnolence, insomnia, sweating, tremor, diarrhea, dyspepsia, anxiety, decreased libido, asthenia, myalgia, rash, and weight gain. ADVERSE EFFECTS: SEVERE: Suicidality, worsening depression, serotonin syndrome, mania, seizure, elevated liver enzymes, hyponatremia, SIADH, priapism, anaphylactoid reaction, hypoglycemia, extrapyramidal reaction, tachycardia, abnormal platelet aggregation, and hepatitis. Abrupt cessation can result in withdrawal syndrome. Escitalopram is the S(+)-enantiomer of citalopram, and the adverse effects profile is similar to that of citalopram. <br\/>"},{"id":"926990-s-12-32","title":"Treatment","mono":"<b>CITALOPRAM AND RELATED AGENTS <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Most patients require only supportive care. Control agitation and confusion with either benzodiazepines or serotonin antagonist such as cyproheptadine or chlorpromazine. Hypertension and tachycardia are generally mild and well tolerated, and do not require specific treatment. MANAGEMENT OF SEVERE TOXICITY: Early intubation, neuromuscular paralysis, ventilation assistance, and aggressive cooling should be performed if the patient presents with respiratory depression, severe muscle rigidity, and severe hyperthermia. Adequate circulatory support with IV fluids and vasopressors (if needed) should be assured if patient presents with circulatory collapse. Treat seizures with benzodiazepines; use barbiturates or propofol for recurrent seizures. Patients with wide-complex dysrhythmias should be treated with hypertonic sodium bicarbonate boluses. Although QTc interval prolongation is well described, torsade de pointes is rare. If torsade de pointes occurs, patients should be treated using standard interventions (magnesium sulfate 2 g IV, external or internal cardiac pacing).<\/li><li>Decontamination: PREHOSPITAL: Activated charcoal can be considered within the first hour after large ingestion (greater than 600 mg citalopram), if the patient has an appropriate level of consciousness, has a patent airway, and is able to drink the charcoal. HOSPITAL: Administer activated charcoal if the patient presents early after large ingestion (greater than 600 mg citalopram), if the patient has an appropriate level of consciousness, patent airway and can drink the charcoal, or if the patient is intubated. Severe toxicity is rare; gastric lavage is rarely, if ever, warranted.<\/li><li>Airway management: Perform early with neuromuscular paralysis if the patient presents with respiratory or CNS depression, severe muscle rigidity, or severe hyperthermia.<\/li><li>Antidote: CYPROHEPTADINE: A serotonin antagonist with high affinity for the 5-HT2 receptors; effective for milder cases of serotonin syndrome. Dose: ADULT: 12 mg orally or nasogastric tube, followed by 4 to 8 mg every 4 to 6 hours. CHILD: 0.25 mg\/kg\/day orally or nasogastric tube divided every 6 hours, maximum dose 12 mg\/day. CHLORPROMAZINE: A phenothiazine antipsychotic with 5-HT2 antagonist activity; indicated in severe serotonin syndrome cases. Dose: 12.5 to 50 mg IV, followed by 25 to 50 mg every 6 hours. It is NOT generally recommended because it may cause severe hypotension.<\/li><li>Seizure: IV benzodiazepines, barbiturates, or propofol for recurrent seizures.<\/li><li>Serotonin syndrome: IV benzodiazepines, cooling measures. Cyproheptadine may be considered (ADULT: 12 mg orally or nasogastric (NG) tube, followed by 4 to 8 mg orally or NG tube every 4 to 6 hours if symptoms persist, up to a maximum of 32 mg in 24 hours. CHILD: 0.25 mg\/kg\/day divided every 6 hours, maximum dose 12 mg\/day). Severe cases have been managed with benzodiazepine sedation and neuromuscular paralysis with nondepolarizing agents.<\/li><li>Torsades de pointes: Hemodynamically unstable patients require electrical cardioversion. Emergent treatment with magnesium or atrial overdrive pacing is indicated. Detect and correct underlying electrolyte abnormalities.<\/li><li>Monitoring of patient: Monitor vital signs (including temperature) and mental status. Monitor serum electrolytes (including potassium, bicarbonate) following significant overdose. Obtain baseline ECG, continuous cardiac monitoring, and serial ECGs following a significant exposure. Monitor serial blood glucose, especially in patients with depressed mental status; severe hypoglycemia has been reported after citalopram overdose. Plasma concentration is not readily available and does not correlate well with therapeutic or adverse effects. It is not indicated for the acute management of overdose.<\/li><li>Enhanced elimination procedure: Hemodialysis and hemoperfusion are NOT of value due to the large volume of distribution.<\/li><li>Patient disposition: HOME CRITERIA: Children and adults with mild symptoms (eg, vomiting, mydriasis, diaphoresis, mild somnolence) following an inadvertent ingestion of up to 100 mg citalopram or 50 mg escitalopram can be managed at home with instructions to call the poison center, if symptoms develop. For patients already on citalopram or escitalopram, those with inadvertent ingestions of up to 5 times their own single therapeutic dose can be observed at home with instructions to call the poison center back if symptoms develop. OBSERVATION CRITERIA: Patients with deliberate ingestions, those with more than mild symptoms, and ingestions of more than 100 mg citalopram or 50 mg escitalopram should be sent to a health care facility. Patients on chronic citalopram or escitalopram therapy should be sent to a healthcare facility if they ingest more than 5 time their own single therapeutic dose. Ingestion of more than 600 mg citalopram or more than 300 mg escitalopram requires cardiac monitoring for 8 hours (11 hours if the patient did not receive activated charcoal within 4 hours of ingestion). Ingestion of more than 1000 mg citalopram or more than 500 mg escitalopram requires cardiac monitoring for 13 hours. At the end of the observation period, if the QTc is less than 450 msec, the monitoring can be discontinued, and the patient may be discharged if asymptomatic. Patients with symptoms of toxicity or a QTc of greater than 450 msec at the end of the observation period should be admitted for continued cardiac monitoring. ADMISSION CRITERIA: Patients with mild to moderate toxicity after intentional overdose need to be monitored for prolonged QTc for at least 13 hours. Patients with severe toxicity need to be admitted to an intensive care unit. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing patients with severe toxicity or an unclear diagnosis.<\/li><\/ul>"},{"id":"926990-s-12-33","title":"Range of Toxicity","mono":"<b>CITALOPRAM AND RELATED AGENTS <\/b><br\/>TOXICITY: Acute ingestion of up to 100 mg citalopram or 50 mg escitalopram is not expected to result in toxicity. Serotonin toxicity may develop at therapeutic doses, particularly if another medication that increases CNS serotonin is used concomitantly. Minor toxicity develops with overdose less than 600 mg citalopram. Ingestion of more than 600 mg citalopram or more than 300 mg escitalopram requires cardiac monitoring for 8 hours (11 hours if the patient did not receive activated charcoal within 4 hours of ingestion). Ingestion of more than 1000 mg citalopram or more than 500 mg escitalopram requires cardiac monitoring for 13 hours. At the end of the observation period, if the QTc is less than 450 msec, the monitoring can be discontinued, and the patient may be discharged if asymptomatic. Patients with symptoms of toxicity or a QTc of greater than 450 msec at the end of the observation period should be admitted for continued cardiac monitoring.  Seizures have been reported after ingestions of more than 600 mg citalopram, and serious toxicity after ingestion of 800 mg or more. PEDIATRIC: QTc prolongation has been reported after ingestion of escitalopram 200 mg. THERAPEUTIC DOSE: ADULT: Citalopram: Initially, 20 mg\/day orally; max dose 40 mg\/day. Escitalopram: 10 to 20 mg\/day orally; max dose 20 mg\/day. PEDIATRIC: Safety and effectiveness in children have not been established.<br\/>"}]},{"id":"926990-s-13","title":"Clinical Teaching","mono":"<ul><li>Counsel patient to report signs or symptoms of serotonin syndrome (high fever, agitation, confusion, hallucinations, hyperreflexia, nausea, vomiting, diarrhea).<\/li><li>Tell patient to avoid activities requiring mental alertness or coordination until drug effects are realized, as drug may impair judgment, thinking, and motor skills.<\/li><li>Drug may cause nausea, somnolence, insomnia, fatigue, or sexual dysfunction (decreased libido, anorgasmia, or ejaculation disorder).<\/li><li>Advise patient that symptomatic improvement may not be seen for a few weeks.<\/li><li>Instruct patient to report worsening depression, suicidal ideation, or unusual changes in behavior, especially with initial dosing and dose changes.<\/li><li>Instruct patient to report signs of hyponatremia (headache, concentration difficulties, confusion, memory impairment, weakness or unsteadiness).<\/li><li>Advise patient against sudden discontinuation of drug.<\/li><li>Instruct patient to not drink alcohol while taking this drug.<\/li><li>Advise patient that concomitant use of aspirin, NSAIDs, warfarin, or other anticoagulants may increase the risk of bleeding.<\/li><li>Advise patient there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use (including over-the-counter and herbal drugs).<\/li><\/ul>"}]}